Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Division of Emergency Medicine, Children's National Hospital, Department of Pediatrics and Emergency Medicine, The George Washington School of Medicine and Health Sciences, Washington, DC, USA.
Am J Gastroenterol. 2021 Jul 1;116(7):1523-1532. doi: 10.14309/ajg.0000000000001295.
It is unclear whether the alleged efficacy of probiotics in childhood acute gastroenteritis depends on the duration and severity of symptoms before treatment.
Preplanned secondary analysis of 2 randomized placebo-controlled trials in children 3-48 months of age was conducted in 16 emergency departments in North America evaluating the efficacy of 2 probiotic products (Lactobacillus rhamnosus GG and a combination probiotic: L. rhamnosus and L. helveticus). Participants were categorized in severity groups according to the duration (<24, 24-<72, and ≥72 hours) and the frequency of diarrhea episodes in the 24 hours (≤3, 4-5, and ≥6) before presentation. We used regression models to assess the interaction between pretreatment diarrhea severity groups and treatment arm (probiotic or placebo) in the presence of moderate-to-severe gastroenteritis (Modified Vesikari Scale score ≥9). Secondary outcomes included diarrhea frequency and duration, unscheduled healthcare provider visits, and hospitalization.
A total of 1,770 children were included, and 882 (50%) received a probiotic. The development of moderate-to-severe gastroenteritis symptoms after the initiation of treatment did not differ between groups (probiotic-18.4% [162/882] vs placebo-18.3% [162/888]; risk ratio 1.00; 95% confidence interval 0.87, 1.16; P = 0.95). There was no evidence of interaction between baseline severity and treatment (P = 0.61) for the primary or any of the secondary outcomes: diarrhea duration (P = 0.88), maximum diarrheal episodes in a 24-hour period (P = 0.87), unscheduled healthcare visits (P = 0.21), and hospitalization (P = 0.87).
In children 3-48 months with acute gastroenteritis, the lack of effect of probiotics is not explained by the duration of symptoms or frequency of diarrheal episodes before presentation.
目前尚不清楚益生菌在儿童急性肠胃炎中的疗效是否取决于治疗前症状的持续时间和严重程度。
在北美 16 家急诊室进行了 2 项随机安慰剂对照试验的预先计划的二次分析,评估了 2 种益生菌产品(鼠李糖乳杆菌 GG 和一种复合益生菌:鼠李糖乳杆菌和瑞士乳杆菌)对 3-48 个月大儿童的疗效。根据就诊前 24 小时内腹泻持续时间(<24 小时、24-<72 小时和≥72 小时)和腹泻次数(≤3 次、4-5 次和≥6 次),将参与者分为严重程度组。我们使用回归模型评估了中度至重度肠胃炎(改良 Vesikari 评分≥9)存在时,治疗前腹泻严重程度组与治疗组(益生菌或安慰剂)之间的相互作用。次要结局包括腹泻频率和持续时间、非计划医疗保健提供者就诊和住院治疗。
共有 1770 名儿童入组,其中 882 名(50%)接受了益生菌治疗。治疗开始后出现中度至重度肠胃炎症状的发生率在两组间无差异(益生菌组 18.4%[162/882],安慰剂组 18.3%[162/888];风险比 1.00;95%置信区间 0.87,1.16;P=0.95)。对于主要结局或任何次要结局,基线严重程度与治疗之间均无交互作用的证据(P=0.61):腹泻持续时间(P=0.88)、24 小时内最大腹泻次数(P=0.87)、非计划医疗保健就诊(P=0.21)和住院治疗(P=0.87)。
在 3-48 个月患有急性肠胃炎的儿童中,益生菌的疗效不佳并非由就诊前症状持续时间或腹泻次数解释。